deListed Australia
 
SEARCH LISTED OR DELISTED COMPANY
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY
SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

KAZIA THERAPEUTICS LIMITED (ASX.KZA)

ASX Announcements (courtesy of ASX)

2017201820192020202120222023

ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)
Former (or subsequent) names
CompanyFROMTO
KAZIA THERAPEUTICS LIMITED29/11/2017
NOVOGEN LIMITED13/05/199729/11/2017
NORVET LIMITED13/05/1997
Shareholder links
Our website ranking of KZA: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Computershare Sydney
Level 3, 60 Carrington Street, Sydney NSW 2000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details
ISIN: AU000000KZA9
Address: Level 5, 20 George St, Hornsby, NSW, 2077Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000
Tel:  + 61 2 9476 0344 Fax: + 61 2 9476 0388

Date first listed: 01/09/1994
Company Secretary: Anna Sandham

Sector: Pharmaceuticals Biotechnology & Life Sciences
Industry Group: XHJ
Activities: Kazia Therapeutics partners with the world's leading researchers and drug developers to bring forward a diversified portfolio of new cancer therapies

delisted at entity's request under Listing Rule 17.11

15/11/2023

we understand the board decided to delist because the administrative time, costs and commercial disadvantages of the listing outweighed the benefits - the company remains listed on NASDAQ

15/11/2023

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, to facilitate its removal from the official list of ASX Limited.

13/11/2023

The suspension of trading in the securities of Kazia Therapeutics Limited will be lifted immediately following the release by KZA of an announcement regarding its proposed delisting on the Official List of ASX.

11/10/2023

Kazia advises that it has submitted a formal application to the ASX to be removed from the official list of the ASX in accordance with ASX Listing Rule 17.11. This formal request follows the receipt of in-principle advice from the ASX in relation to the proposed Delisting, subject to the satisfaction of some conditions.

11/10/2023

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding the proposed trading solely on Nasdaq and proposed delisting of KZA's securities from ASX.

10/10/2023

The suspension of trading in the securities of Kazia Therapeutics Limited will be lifted immediately, following the release by KZA of an announcement regarding a capital raising.

18/10/2018

The company completes a placement of KZA shares, primarily to sector-specialist institutional investors in Australia and internationally, at a price of A$0.38 per share. The placement will raise approximately A$3.4 million. Kazia will launch a share purchase plan to allow eligible existing holders of KZA securities the opportunity to acquire new fully-paid ordinary shares on the same terms as the placement. The SPP will open on Tuesday 23 October 2018.

18/10/2018

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding a potential capital raising.

17/10/2018

name changed from Novogen Limited

29/11/2017
View ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates
Post your comments here
Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    07/09/2022James Garner100,000$0.231$23,135
    07/09/2022Steven Coffey50,000$0.222$11,118
    06/09/2022Bryce Carmine120,000$0.235$28,200
    06/09/2022Iain Ross175,000$0.221$38,623
    20/12/2021Steven Coffey50,000$1.090$54,480

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    NAMETITLEDATE OF APPT
    Karen KrumeichCFO01/01/2021
    Bryce CarmineNon Exec Director03/06/2015
    Ebru DavidsonNon Exec Director05/06/2023
    Steven CoffeyNon Exec Director08/11/2012
    John FriendInterim Chairman, CEO01/05/2023

    Date of first appointment, title may have changed.

    Directors & Executives (former)
    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Iain RossNon Exec Chairman22/07/201511/08/2023
    James GarnerExecutive Director, CEO01/02/201601/05/2023
    Mark HinzeCFO18/06/201001/01/2021
    John O'ConnorNon Exec Chairman25/05/201208/06/2017
    Ian PhillipsNon Exec Director03/06/201508/06/2017
    Peter GunningNon Exec Director04/03/201405/09/2016
    Christopher CoxExecutive Director, CEO07/12/201222/07/2015
    Robert BirchDeputy Chairman, Non Exec Director12/12/201204/03/2014
    Andrew HeatonExecutive Director07/12/201204/03/2014
    Josiah AustinNon Exec Director20/09/201019/04/2013
    William RueckertChairman23/03/200907/12/2012
    Peter WhiteNon Exec Director20/09/201007/12/2012
    Ross YoungmanNon Exec Director20/09/201008/11/2012
    Peter ScuttNon Exec Director29/10/201025/05/2012
    Geoffrey LeppinusNon Exec Director24/02/200529/10/2010
    Philip JohnstonNon Exec Chairman01/01/199718/10/2010
    Christopher NaughtonManaging Director, CEO01/03/199701/12/2009

    Date of first appointment, title may have changed.